IPCI


Stock Update (NASDAQ:IPCI): IntelliPharmaCeutics Intl Inc (USA) Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program Due To Positive Feedback from FDA

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid …

Brean Capital Reiterates Buy on IntelliPharmaCeutics Intl Inc (USA) Following 1Q:15 Update

In a research report released Tuesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) with an $8.00 price …

Stock Update (NASDAQ:IPCI): Intellipharmaceutics Intl Inc (USA) Announces First Quarter 2015 Results

Intellipharmaceutics Intl Inc (USA) (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid …

Brean Capital Offers Commentary on IntelliPharmaCeutics Intl Inc (USA) Following Clincal Updates

Brean Capital analyst Jonathan Aschoff weighed in today with a few insights on IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), after the company provided an update on the progress of the product …

Stock Update (NASDAQ:IPCI): Intellipharmaceutics Reports Positive Topline Data Results from a Series of Phase I Clinical Trials of its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, and files an IND for Rexista(TM) Oxycodone XR

Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic …

Stock Update (NASDAQ:IPCI): Intellipharmaceutics Announces 2014 Year End Results With a 48% Reduction in Operating Loss

Intellipharmaceutics International Inc. (Nasdaq:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid …

Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals

hares of IntelliPharmaceutics International  (NASDAQ: IPCI) saw a nearly 6% increase in trading on Tuesday, February 2nd following the company’s announcement that it has signed …

Brean Capital Comments On Intellipharmaceutics Following Licensing Agreement With Teva

Brean Capital analyst Jonathan Aschoff came out today with a research note on Intellipharmaceutics (NASDAQ:IPCI), as the company announced a licensing agreement with Teva …

Maxim Maintains Buy On Intellipharmaceutics Following License Agreement With Teva

Maxim’s healthcare analyst Jason Kolbert is weighing in with an update on Intellipharmaceutics International (NASDAQ:IPCI), as the company announced the it has signed a license agreement …

Maxim Maintains Buy On Intellipharmaceutics Following Regabatatin XR Update

In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Intellipharmaceutics International (NASDAQ:IPCI) with a $7 price target, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts